A Non-Antibiotic-Disrupted Gut Microbiome Is Associated with Clinical Responses to CD19-CAR-T Cell Cancer Immunotherapy

In a B cell lymphoma patient cohort from five centers in Germany and the United States, the authors demonstrated that wide-spectrum antibiotics treatment prior to CD19-targeted CAR-T cell therapy was associated with adverse outcomes, but this effect was likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with such antibiotics.
[Nature Medicine]
AbstractPress Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News